Navigation Links
EntreMed's Aurora Kinase Inhibitor Induces Tumor Regression in,Preclinical Models

ROCKVILLE, Md., June 01, 2007 /PRNewswire-FirstCall/ -- EntreMed, Inc. , a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, announced the presentation of preclinical results for its Aurora kinase - angiogenesis inhibitor, ENMD-981693. The data were presented during oral and poster presentations by EntreMed scientists at the 2nd Protein Kinases in Drug Discovery Conference being held May 31 - June 1, 2007 in Boston, Massachusetts.

ENMD-981693 is an oral, dual-acting kinase inhibitor with a unique kinase selectivity profile and multiple mechanisms of action. In preclinical studies, ENMD-981693 has been shown to inhibit a unique profile of angiogenic tyrosine kinase targets in addition to the Aurora kinases. Aurora kinases are key regulators of mitosis (cell division), and are often over-expressed in human cancers. ENMD-981693 is selective for the Aurora A isoform in comparison to Aurora B.

Results from in vitro studies demonstrate ENMD-981693's potent activity against oncogenic receptor tyrosine kinases, including FLT3, c-Kit and CSF1R, which are involved in the pathology of hematological cancers. Additionally, ENMD-981693 demonstrated potent inhibition of a spectrum of targets linked to angiogenesis, including KDR (VEGFR2) and FGFR1. The compound was also shown to induce apoptosis and cell cycle arrest in a broad range of cell lines.

ENMD-981693 exhibited antiangiogenic activity in in vivo animal models by preventing the formation of new blood vessels and inducing regression of formed vessels at well-tolerated doses. Orally-administered ENMD-981693 induced tumor regression with minimal toxicity in a preclinical xenograft model of human leukemia. This activity is consistent with tumor regression induced by ENMD-981693 in preclinical models of human tumors derived from colon, leukemia, and breast cancer cell lines.

Mark
'"/>




Page: 1 2 3

Related medicine technology :

1. Clinical Results From EntreMeds Panzem NCD and Taxol Breast Cancer Study Presented at ASCO
2. Phase 2 Results for EntreMeds Panzem NCD Brain Cancer Study Presented at ASCO
3. Sunesis Pharmaceuticals Presents SNS-314 Aurora Kinase Inhibitor Data Showing Broad Anti-Tumor Activity, Dosing Flexibility
4. Data Show SuperGens Multi-Targeted Tyrosine Kinase Inhibitor Suppresses Critical Double-Stranded DNA Repair Protein, Rad51
5. Pharmacyclics Identifies Functional Biomarkers for its Novel HDAC Inhibitor and Demonstrates Preclinical Anti-Tumor Activity with Brutons Tyrosine Kinase Inhibitors
6. AVEO Presents Preclinical Efficacy Data on AV-412, a Novel Oral Tyrosine Kinase Inhibitor of EGFR/HER2 for EGFR Mutant and Drug-Resistant Lung Cancer
7. Pharmacyclics Announces Presentations on Its Novel and Selective HDAC and Brutons Tyrosine Kinase Inhibitor Compounds
8. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Major New Review Supports the Broader Potential of CeNeS COMT Inhibitor Discovery Programme
10. Arisaph Pharmaceuticals Announces Results of its Potent Smart DPP-4 Inhibitor, ARI-2243, at the ADA
11. Anadys Pharmaceuticals Nominates ANA598, a Small-Molecule, Non-Nucleoside Inhibitor of The NS5b Polymerase, as a Candidate for Clinical Development in Chronic Hepatitis C Virus Infection

Post Your Comments:
(Date:11/24/2009)... PITTSBURGH,Nov.24/PRNewswire/-- ,, WHAT:RomHou...ollowinganautoaccident,wasactuallyfullyconsciousan...Americasegment.TheDynaVoxEyeMaxwasfeaturedintheseg...therconditionscanunlockcommunication. ,, WHEN:G...lineat www.dynavoxtech.com ,, WHO:RomHou...
(Date:11/24/2009)... FREMONT,Calif.,Nov.24/PRNewswire-FirstCall/--Verm...panyfileditsPlanofReorganizationandDisclosureState...uptcyCourtfortheDistrictofDelaware.Ahearingtoconsi...duledforDecember8,2009,withthehearingontheconfirma...lancallsfortheCompanytopayallclaimsinfull.ThePlani...
(Date:11/24/2009)... POTOMAC,Md.,Nov.24/PRNewswire/--Inadditiontofamil...ddedPhiladelphiajurorstoherThanksgivinggratitudeli...amsothankfultothem,"shesaidofMonday,sverdictstotal.... ,, Wisneskiisamong12,000womennationwidewhohav...onetherapydrugsPremarinandPrempro.Wisneskiandtheot...
Breaking Medicine Technology:DynaVox EyeMax Featured in Good Morning America Segment About Man Thought To Be in Coma for 23 Years 2Vermillion Files Plan of Reorganization 2Vermillion Files Plan of Reorganization 3Maryland Woman Thankful for Wyeth Verdicts 2Millennium Pharmacy Adds First Client in New England 6334 1Millennium Pharmacy Adds First Client in New England 6334 2Lung cancer experts hold roundtable on new staging guide 61518 1Lung cancer experts hold roundtable on new staging guide 61518 2Worlds first delivery of intra arterial Avastin directly into brain tumor 61515 1Worlds first delivery of intra arterial Avastin directly into brain tumor 61515 2Worlds first delivery of intra arterial Avastin directly into brain tumor 61515 3
...resented at ASCO Breast Cancer Symposium; Addition...n at ASCO Annual Meeting in June, Phase I Trial ... Plus Paclitaxel Regimen...corporated (Nasdaq: KOSN ) presented updated data...imycin, its second-generation Hsp90 inhibitor,demo...
...ng Bavituximab to Standard Regimen of Androgen Dep...y Resistant Tumors by More than Half - - Data Fu...ultiple Combination Regimens for Can... 7 ,Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM...eloping targeted monoclonal antibodies for the,tre...
Other Medicine Technology:Kosan's Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial 2Kosan's Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial 3Kosan's Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial 4Kosan's Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial 5Peregrine Researchers Report Data Showing Bavituximab's Potential to Shrink Human Prostate Tumors in Model of Relapsed Disease 2Peregrine Researchers Report Data Showing Bavituximab's Potential to Shrink Human Prostate Tumors in Model of Relapsed Disease 3Peregrine Researchers Report Data Showing Bavituximab's Potential to Shrink Human Prostate Tumors in Model of Relapsed Disease 4
(Date:11/26/2009)...omolybdate (TM) has been shown in studies to be ef...ase caused by an overload of copper, and certain m..., however, is known about how the drug works at th...tern University researchers now has provided an in...TM bound to copper-loaded metallochaperones. The d...
(Date:11/26/2009)... of the Live Life Again Center, a practice offerin...wing number of physicians who are taking advantag...th individuals who are interested in surgical weig... is utilizing Facebook to share before-and-after p...community. , Dallas, TX (...
(Date:11/25/2009)...SNewswire/--WhenmostpeopleheartheacronymTMJ,theyth...ntsthehelptheyneed.TMJstandsfortheTemporal-Mandibu...nectswithyourskull(temporalbone). ,, Themostcom...chewing,clickingorpoppingofthejaw.Butmanyothersymp...es,fatigue,sleepdisturbances,irritability,alossinf...
(Date:11/25/2009)...inelleMedicalInc.,aleadingmanufacturerofbreastMRIc...ofnewleadingedgeclinicalapplicationsonitsAegis(TM)...icalSocietyofNorthAmerica(RSNA)annualmeetinginChic...ionsleveragetheuniquehighqualityimagesgeneratedbyS...tipleimagingmodalitiesformulti-parametricassessmen...
(Date:11/25/2009)...--TheBayAreaAirQualityManagementDistrictisissuingt...lert forThursday,November26,2009whichbansburning...ndoorsandoutdoors. ,, "Cold,stillweatherwillcon...dbent,executiveofficeroftheAirDistrict."We,reaskin...sandfellowcommunitymembersthisThanksgiving,andnott...
Breaking Medicine News(10 mins):Health News:Research sheds light on workings of anti-cancer drug 2Health News:Research sheds light on workings of anti-cancer drug 3Health News:Dallas Texas Weight Loss Surgeon Using Social Media To Reach Out to Patients 2Health News:Dallas Texas Weight Loss Surgeon Using Social Media To Reach Out to Patients 3Health News:Sentinelle Medical Launches Aegis Suite of Oncology 4D Visualization Software with PureWeb(TM) Technology 2Health News:Sentinelle Medical Launches Aegis Suite of Oncology 4D Visualization Software with PureWeb(TM) Technology 3Health News:Winter Spare the Air Alert in Effect for Thursday, November 26, 2009 2
...tees of the National Institute of Allergy and Infe...itutes of Health (NIH), unexpectedly //discovered ...oma, while investigating a fungus known to cause a...ng an antibody with radiation, has since been furt...
...e of New Jersey has reached an agreement to suppor...udies. This latest legislation comes// three years...m cell research, being only the second state in US...mblyman Neil M Cohen from D-Union who is one of th...
...g to the latest findings of the researchers at May...lar painkillers reduces the risk of developing// e...study were published in the American Journal of Ep...ors. More than half of the men in their seventies ...
...a half months after his sexual organ was completel...to lead a normal life again after a Delhi hospital... The unmarried man from Uttar Pradesh underwent...e incident occurred around 8 p.m. in a city around...
...ften by cultural or linguistic isolation, young Hi...xceptionally high risk //of attempting or committi... The problem is mainly fuelled by cultural and ...in Lower Manhattan on Friday. In New York, A...
...r Tickle Me Elmo. The recently released Nintendo W...ling the giggling red monster as the gifts childre... As coveted as these new video game systems an...ays. With more educational games hitting st...
Other Medicine News:Health News:Researchers Develop Basis For Experimental Melanoma Treatment 2Health News:Researchers Develop Basis For Experimental Melanoma Treatment 3Health News:New Jersey Decides to Support $500 M Stem Cell Research 2Health News:Delhi Hospital Reattaches Amputated Penis 2Health News:Video Games Fun but Pose Social, Health Risks 2Health News:Video Games Fun but Pose Social, Health Risks 3
LabPak POL Plus Laboratory Information System
...es from Cardinal Health will change the way you th...Shrinking budgets and reduced reimbursements mean ...ithout sacrificing the quality of care or jeopardi...ated from the perspective of total value and long-...
NEAR-SkinT™ Incise Drape
...ade of 3M™ Steri-Drape™ Absorbent Impe... a sterile field during procedures on extremities....nient by eliminating the need for multiple drapes....apertures suitable for surgical procedures on legs...
Medicine Products: